Chemotherapy plus immunotherapy before lung cancer surgery
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of chemotherapy and immunotherapy given before surgery for stage II or III non-small cell lung cancer. Doctors will look at biomarkers in your blood and tissue to see how the cancer responds, which could help guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage II or III non-small cell lung cancer (confirmed by biopsy).
- Your tumor does not have an EGFR mutation or ALK gene change.
- You are physically active enough to do light work or normal daily activities (ECOG 0 or 1).
- You are 20 years old or older.
- You do not have serious infections or other medical problems that would make the trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of an immunotherapy drug (IBI363) plus chemotherapy before surgery in people with Stage III lung cancer that can't be removed at first. The goal is to shrink the tumor so it can be surgically removed.
This trial looks at giving immunotherapy before surgery for certain early-stage lung cancers to help shrink the tumor and improve outcomes. It is mainly for people whose lung cancer can be removed by surgery and who don’t have specific gene changes like EGFR or ALK.
This trial compares giving immunotherapy before and after surgery versus only after surgery for people with early-stage but advanced lung cancer. It aims to see which timing might better help keep the cancer from coming back.
This study looks at a treatment plan that uses immunotherapy before and after surgery for non-small cell lung cancer. The goal is to see if this approach helps patients do better and to find out which patients benefit most.
This study looks at using immunotherapy before surgery for stage II-III lung cancer. It aims to find markers that predict how well this treatment works, potentially leading to more personalized care.
This trial tests whether giving immunotherapy before surgery helps people with lung cancer. It is for patients who have already started this treatment and are otherwise healthy.
Hear when a new Clinical Stage II to III Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.